Pharmacological treatments for smoking cessation.
systematic_review · Level I
Where this comes from
- Record sourced from PubMed, PMID 24399558.
- Also identified by DOI 10.1001/jama.2013.283787.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Among the 3 first-line smoking cessation treatments (nicotine replacement therapy [NRT], bupropion, and varenicline), which is most effective in helping people who smoke achieve and maintain abstinence from smoking for at least 6 months, and what serious adverse events are associated with each? Higher rates of smoking cessation were associated with NRT (17.6%) and bupropion (19.1%) compared with placebo (10.6%). Varenicline (27.6%) and combination NRT (31.5%) (eg, patch plus inhaler) were most effective for achieving smoking cessation. None of the therapies was associated with an increased rate of serious adverse events.
Medical subject headings
- Antidepressive Agents, Second-Generation
- Benzazepines
- Bupropion
- Nicotinic Agonists
- Quinoxalines
- Smoking Cessation
- Tobacco Use Cessation Devices